IP Library Granted Patent US 10,653,716
Granted Patent B2
US 10,653,716 · App. 16/137,447 · Granted May 19, 2020

Injectable monophase hydrogels

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: ALLERGAN INDUSTRIE, SAS
A61K31/738A61K9/0019A61L27/20A61L27/50A61L27/52C08B37/0072C08J3/24C08L5/08C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,716
App. No.
16/137,447
Granted
May 19, 2020
Kind
B2
Abstract

An injectable monophase hydrogel is provided that is made of a reaction mixture of hyaluronic acids having different molecular weights.

Claims (22)

1. An injectable composition comprising a hyaluronic acid gel, the hyaluronic acid gel comprising:

about 5% by weight to about 50% by weight of a first hyaluronic acid having a molecular weight of about 3×10 6 Da; and

about 50% by weight to about 95% by weight of a second hyaluronic acid having a molecular weight of about 3×10 5 Da;

wherein the hyaluronic acid gel is crosslinked via covalent bonding between a bifunctional crosslinker and hydroxyl moieties of the first and second hyaluronic acids; and further wherein the hyaluronic acid gel has a Tan δ 1 Hz in the range of about 0.07 to about 0.12.

2. The injectable composition of claim 1 , wherein the hyaluronic acid gel comprises about 5% by weight to about 30% by weight of the first hyaluronic acid.

3. The injectable composition of claim 1 , wherein the hyaluronic acid gel comprises about 70% by weight to about 95% by weight of the second hyaluronic acid.

4. The injectable composition of claim 1 , wherein the bifunctional crosslinker is selected from the group consisting of bifunctional crosslinking agents epichlorohydrin, divinyl sulfone, 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidoxybutane, 1,4-butanediol diglycidyl ether (BDDE)), 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, formaldehyde, glutaraldehyde, and crotonaldehyde.

5. The injectable composition of claim 4 , wherein the bifunctional crosslinker is (BDDE).

6. The injectable composition of claim 1 having a concentration of hyaluronic acid gel of between 10 and 40 mg/g.

7. The injectable composition of claim 1 having a concentration of hyaluronic acid gel of between 20 and 30 mg/g.

8. The injectable composition of claim 1 having a concentration of hyaluronic acid gel of 26 mg/g.

9. The injectable composition of claim 1 , wherein the first hyaluronic acid has a first intrinsic viscosity and the second hyaluronic acid has a second intrinsic viscosity different from the first intrinsic viscosity.

10. The injectable composition of claim 1 , wherein hyaluronic acid gel comprises the first hyaluronic acid and the second hyaluronic acid in a weight ratio of 10:90, respectively.

11. The injectable composition of claim 1 , wherein the hyaluronic gel is homogenized.

12. The injectable composition of claim 1 , wherein the injectable composition is sterilized.

13. The injectable composition of claim 1 , wherein the injectable composition further comprises an aqueous solution buffered to a pH of between 6.5 and 7.5.

14. The injectable composition of claim 13 , wherein the aqueous solution is a phosphate buffer.

15. The injectable composition of claim 14 , wherein the aqueous solution is buffered to a pH of between 7.1 and 7.3.

16. The injectable composition of claim 1 , wherein the hyaluronic gel is a monophase hyaluronic acid hydrogel.

17. The injectable composition of claim 1 , wherein the injectable composition has an injectability of about 12 to about 17 Newtons as measured in a standard syringe having a needle of 27 G½, at a rate of 12.5 mm/min.

18. The injectable composition of claim 1 , wherein the hyaluronic acid gel has a degree of crosslinking from about 0.5% to about 70%.

19. The injectable composition of claim 18 , wherein the degree of crosslinking is between about 4% and about 50%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2021
From: LEBRETON, PIERRE
To: CORNEAL INDUSTRIE
Reel/Frame 055884/0420 →
CHANGE OF NAME Recorded Apr 11, 2021
From: CORNEAL INDUSTRIE
To: ALLERGAN INDUSTRIE, SAS
Reel/Frame 055884/0426 →
Priority Claims (1)
FR 03 0444 · Apr 10, 2003 · national
Continuity (7)
Continuation 15209561 · Jul 13, 2016
Continuation 14535220 · Nov 6, 2014
Continuation 14024916 · Sep 12, 2013
Continuation 13566767 · Aug 3, 2012
Continuation 12782488 · May 18, 2010
Division 10552309
Related Publication 20190022130A1 · Jan 24, 2019